A groundbreaking study has unveiled that Novo Nordisk’s (NYSE:NVO) “miracle’ weight loss drug Ozempic and similar GLP-1 receptor agonists could significantly lower the risk of alcohol and opioid overdoses. This discovery suggests potential new applications for these drugs, which are primarily used for treating obesity and diabetes. What Happened: Research published in the journal Addiction indicates that GLP-1 drugs like Ozempic may play a crucial role in reducing substance abuse, Financial Times reported on Thursday. The study examined data from over 500,000 individuals with opioid-use disord…
